Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest brain metastases Stories

2013-11-19 12:29:24

HAIFA, Israel, Nov. 19, 2013 /PRNewswire/ -- Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF(TM) Therapy for patients with brain metastases from non-small cell lung carcinoma (NSCLC) cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System. "The EF-21 Study builds on extensive preclinical research on the effect of NovoTTF Therapy in...

2013-09-23 13:04:18

When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. Younger patients (under 50 years old) were also found to be at no greater risk of new brain metastases developing despite omission of WBRT. A highly advanced...

2012-05-18 23:51:29

3-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet. The drug dabrafenib, which targets the Val600 BRAF mutation that is active in half of melanoma cases, also cut the size of tumors in 25 of 36...

2010-12-09 18:47:06

Early identification of women at risk might allow preventive therapy and prolong survival Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies...

2010-10-12 16:47:48

A new drug being developed to treat potentially deadly melanoma skin cancers has shown a promising ability to shrink secondary tumors, known as metastases, in the brain in patients with advanced forms of the disease, Australian researchers report. At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Georgina Long from Melanoma Institute Australia and Westmead Hospital, in Sydney, reported the results in a subgroup of 10 melanoma patients with previously untreated brain...

2010-07-01 08:00:00

ATLANTA, July 1 /PRNewswire/ -- The refinements in Elekta's Gamma Knife® surgery technology that created the fifth generation Leksell Gamma Knife® Perfexion(TM) are radically changing the approach to treating brain metastases and other brain disorders. With Perfexion, physicians are applying therapy to multiple metastases (mets) in a single session, treating more non-malignant targets located in critical areas and planning increasingly tailored plans to...

2010-05-27 06:30:00

MISSISSAUGA, ON, May 27 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and...

2010-04-29 08:00:00

ATLANTA and PHILADELPHIA, April 29 /PRNewswire/ -- At the 2010 American Association of Neurological Surgeons (AANS) Annual Meeting, May 1-5 at the Pennsylvania Convention Center, Elekta will host a series of presentations highlighting Elekta Neuromag®, a tool that measures and records brain activity using magnetoencephalography (MEG) technology. Led by Froedert & Medical College of Wisconsin neurosurgeon, Brian Kopell, M.D., the sessions will take place at Elekta...

2010-01-26 06:30:00

MISSISSAUGA, ON, Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC....

46cc534a0fae79d6b039eef9687929061
2009-12-20 13:25:50

Up to 25% of cancer patients develop metastases in the brain "“ often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious. Now a research team led by neurologist Dr. Frank Winkler of LMU Munich has followed, in real time, the steps that lead some tumor cells to establish metastases, while others fail to form new tumors. The team also discovered...